Thomas Kruse and Søren Østergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Obesity Atlas 2023 (World Obesity Federation, 2023)
Drucker, D. J., Habener, J. F. & Holst, J. J. J. Clin. Invest. 127, 4217–4227 (2017).
Kurtzhals, P., Østergaard, S., Nishimura, E. & Kjeldsen, T. Nat. Rev. Drug Discov. 22, 59–80 (2022).
Kurtzhals, P. et al. Biochem. J. 312, 725–731 (1995).
Knudsen, L. B. et al. J. Med. Chem. 43, 1664–1669 (2000).
Lau, J. et al. J. Med. Chem. 58, 7370–7380 (2015).
Garvey, W. T. et al. Nat. Med. 28, 2083–2091 (2022).
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) (US National Library of Medicine, 2023); https://classic.clinicaltrials.gov/ct2/show/NCT03574597
Tschöp, M. H. et al. Cell Metab. 24, 51–62 (2016).
Jastreboff, A. M. et al. New Engl. J. Med. 387, 205–216 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.K. and S.O. are employees and shareholders of Novo Nordisk.
Rights and permissions
About this article
Cite this article
Kruse, T., Østergaard, S. Redefining peptide therapeutics with semaglutide. Nat. Chem. 16, 296 (2024). https://doi.org/10.1038/s41557-023-01434-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41557-023-01434-4